IN2015DN02829A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN02829A IN2015DN02829A IN2829DEN2015A IN2015DN02829A IN 2015DN02829 A IN2015DN02829 A IN 2015DN02829A IN 2829DEN2015 A IN2829DEN2015 A IN 2829DEN2015A IN 2015DN02829 A IN2015DN02829 A IN 2015DN02829A
- Authority
- IN
- India
- Prior art keywords
- compound
- formula
- effective amount
- therapeutically effective
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011001692 | 2011-10-10 | ||
PCT/EP2012/069936 WO2013053690A1 (en) | 2011-10-10 | 2012-10-09 | Pde9i with imidazo pyrazinone backbone |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN02829A true IN2015DN02829A (fi) | 2015-09-11 |
Family
ID=47019007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2829DEN2015 IN2015DN02829A (fi) | 2011-10-10 | 2012-10-09 |
Country Status (15)
Country | Link |
---|---|
US (2) | US9643970B2 (fi) |
EP (2) | EP2906562B1 (fi) |
JP (1) | JP2015531401A (fi) |
CN (2) | CN104703987B (fi) |
AU (2) | AU2012323085B2 (fi) |
BR (1) | BR112015007731B1 (fi) |
CA (1) | CA2886885C (fi) |
HK (1) | HK1211023A1 (fi) |
IL (2) | IL237836A (fi) |
IN (1) | IN2015DN02829A (fi) |
MA (1) | MA37958B1 (fi) |
MX (1) | MX370433B (fi) |
SG (1) | SG11201502728WA (fi) |
TN (1) | TN2015000100A1 (fi) |
WO (1) | WO2013053690A1 (fi) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2886885C (en) * | 2011-10-10 | 2019-07-16 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
AU2015217073B2 (en) | 2014-02-13 | 2019-08-22 | Incyte Holdings Corporation | Cyclopropylamines as LSD1 inhibitors |
EP3105226B1 (en) | 2014-02-13 | 2019-09-04 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
JO3627B1 (ar) * | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
SI3865484T1 (sl) * | 2015-07-07 | 2024-05-31 | H. Lundbeck A/S | Zaviralec pde9 z imidazo pirazinonsko hrbtenico za zdravljenje perifernih bolezni |
TW201717948A (zh) * | 2015-08-10 | 2017-06-01 | H 朗德貝克公司 | 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療 |
WO2017027678A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Salts of an lsd1 inhibitor |
LT3374359T (lt) * | 2015-11-09 | 2020-03-25 | Astrazeneca Ab | Dihidroimidazopirazinono deriniai, tinkami panaudoti vėžio gydymui |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
BR112018071585B1 (pt) | 2016-04-22 | 2024-01-02 | Incyte Corporation | Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas |
WO2018009424A1 (en) * | 2016-07-06 | 2018-01-11 | Imara, Inc. | Pde9 inhibitors for treatment of peripheral diseases |
ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
SI3532064T1 (sl) * | 2016-10-28 | 2020-10-30 | H. Lundbeck A/S | Kombinirana zdravljenja, ki obsegajo imidazopirazinone za zdravljenje psihiatričnih in/ali kognitivnih motenj |
JP2020500841A (ja) * | 2016-10-28 | 2020-01-16 | ハー・ルンドベック・アクチエゼルスカベット | イミダゾピラジノンの投与を含む併用療法 |
JP2020509004A (ja) * | 2017-02-27 | 2020-03-26 | ヤンセン ファーマシューティカ エヌ.ベー. | Oga阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている[1,2,4]−トリアゾロ[1,5−a]−ピリミジニル誘導体 |
PT3630772T (pt) * | 2017-05-26 | 2024-02-05 | Cardurion Pharmaceuticals Inc | Métodos para fabricar e usar inibidores de pde9 |
AU2018281131B2 (en) | 2017-06-08 | 2022-01-20 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine PDE9 inhibitors |
US11147275B2 (en) | 2017-11-23 | 2021-10-19 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
JP2021526134A (ja) | 2018-05-25 | 2021-09-30 | イマラ インク. | 6−[(3S,4S)−4−メチル−l−(ピリミジン−2−イルメチル)ピロリジン−3−イル]−3−テトラヒドロピラン−4−イル−7H−イミダゾ[l,5−A]ピラジン−8−オンの一水和物および結晶形態 |
WO2019243528A1 (en) * | 2018-06-20 | 2019-12-26 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
CA3136128A1 (en) * | 2019-04-05 | 2020-10-08 | Imara Inc. | Pde9 inhibitors for treating sickle cell disease |
WO2020227399A1 (en) * | 2019-05-07 | 2020-11-12 | Imara Inc. | Pde9 inhibitors for treating thalassemia |
WO2022036111A1 (en) * | 2020-08-13 | 2022-02-17 | Imara Inc. | Methods and compositions for treating sickle cell disease |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA46166C2 (uk) | 1997-11-12 | 2002-05-15 | Баєр Акцієнгезельшафт | 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі |
KR20010101603A (ko) | 1999-01-20 | 2001-11-14 | 노왈드 | 이미다조[1,5-a]-피리도[3,2-e]-피라지논의 약제로서의용도 |
KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Pde9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
GB2388111A (en) | 2002-05-01 | 2003-11-05 | Bayer Ag | Novel imidazotriazinone compounds |
US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
CA2543522A1 (en) | 2003-10-31 | 2005-05-12 | Pfizer Products Inc. | Phosphodiesterase 9 inhibition as treatment for obesity-related conditions |
WO2007028051A2 (en) | 2005-09-02 | 2007-03-08 | Abbott Laboratories | Novel imidazo based heterocycles |
TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
CA2662594A1 (en) | 2006-09-08 | 2008-03-13 | Tokuyama Corporation | Method and apparatus for producing a group iii nitride |
EP2103613B1 (en) | 2006-12-13 | 2016-02-17 | ASKA Pharmaceutical Co., Ltd. | Quinoxaline derivative |
CA2672591A1 (en) * | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | Treating agent of uropathy |
GEP20125405B (en) | 2007-05-11 | 2012-02-27 | Pfizer | Amino-heterocyclic compounds |
DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
US9260432B2 (en) | 2009-09-02 | 2016-02-16 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
ES2610360T3 (es) * | 2010-09-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Compuestos de imidazotriazinona |
JO3116B1 (ar) | 2011-10-07 | 2017-09-20 | Eisai R&D Man Co Ltd | مشتق بيرازولوكينولين كمثبطات ل pde9 |
CA2886885C (en) * | 2011-10-10 | 2019-07-16 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
US9434733B2 (en) | 2012-01-26 | 2016-09-06 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone |
WO2013142269A1 (en) | 2012-03-19 | 2013-09-26 | Envivo Pharmaceuticals, Inc. | Imidazotriazinone compounds |
-
2012
- 2012-10-09 CA CA2886885A patent/CA2886885C/en active Active
- 2012-10-09 JP JP2015535994A patent/JP2015531401A/ja active Pending
- 2012-10-09 EP EP12772769.1A patent/EP2906562B1/en active Active
- 2012-10-09 AU AU2012323085A patent/AU2012323085B2/en active Active
- 2012-10-09 BR BR112015007731-5A patent/BR112015007731B1/pt active IP Right Grant
- 2012-10-09 CN CN201280076285.6A patent/CN104703987B/zh active Active
- 2012-10-09 SG SG11201502728WA patent/SG11201502728WA/en unknown
- 2012-10-09 US US14/434,308 patent/US9643970B2/en active Active
- 2012-10-09 CN CN201710247417.1A patent/CN106905324B/zh active Active
- 2012-10-09 MX MX2015004422A patent/MX370433B/es active IP Right Grant
- 2012-10-09 MA MA37958A patent/MA37958B1/fr unknown
- 2012-10-09 WO PCT/EP2012/069936 patent/WO2013053690A1/en active Application Filing
- 2012-10-09 EP EP16185105.0A patent/EP3121178B1/en active Active
- 2012-10-09 IN IN2829DEN2015 patent/IN2015DN02829A/en unknown
-
2015
- 2015-03-16 TN TNP2015000100A patent/TN2015000100A1/fr unknown
- 2015-03-19 IL IL237836A patent/IL237836A/en active IP Right Grant
- 2015-11-27 HK HK15111740.3A patent/HK1211023A1/xx unknown
-
2017
- 2017-03-08 US US15/452,827 patent/US9993477B2/en active Active
- 2017-03-20 AU AU2017201873A patent/AU2017201873C1/en active Active
- 2017-07-12 IL IL253448A patent/IL253448A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2906562A1 (en) | 2015-08-19 |
SG11201502728WA (en) | 2015-05-28 |
BR112015007731A2 (pt) | 2017-07-04 |
US20150274736A1 (en) | 2015-10-01 |
CN106905324B (zh) | 2018-09-25 |
MA37958B1 (fr) | 2018-10-31 |
CA2886885A1 (en) | 2013-04-18 |
US20170173018A1 (en) | 2017-06-22 |
MX2015004422A (es) | 2015-10-15 |
JP2015531401A (ja) | 2015-11-02 |
CA2886885C (en) | 2019-07-16 |
AU2017201873B2 (en) | 2018-03-29 |
AU2012323085A1 (en) | 2015-04-02 |
HK1211023A1 (en) | 2016-05-13 |
IL237836A (en) | 2017-07-31 |
CN104703987B (zh) | 2017-05-03 |
WO2013053690A1 (en) | 2013-04-18 |
CN106905324A (zh) | 2017-06-30 |
EP2906562B1 (en) | 2016-10-05 |
MA37958A1 (fr) | 2017-11-30 |
US9643970B2 (en) | 2017-05-09 |
AU2017201873C1 (en) | 2018-08-02 |
AU2017201873A1 (en) | 2017-04-06 |
MX370433B (es) | 2019-12-13 |
AU2012323085B2 (en) | 2017-03-09 |
CN104703987A (zh) | 2015-06-10 |
BR112015007731B1 (pt) | 2022-05-31 |
IL253448A0 (en) | 2017-09-28 |
TN2015000100A1 (en) | 2016-06-29 |
US9993477B2 (en) | 2018-06-12 |
EP3121178B1 (en) | 2018-09-19 |
EP3121178A1 (en) | 2017-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN02829A (fi) | ||
PH12014501695B1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
TN2012000287A1 (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
MY152949A (en) | Novel phenylimidazole derivatives as pde10a enzyme inhibitors | |
JO3089B1 (ar) | مشتقات ايميدازول كمثبطات لانزيمات pde10a | |
UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a | |
TN2012000271A1 (en) | Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors | |
MY156520A (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors | |
MX2013012588A (es) | Inhibidores de cinasa. | |
MX336915B (es) | Derivados de imidazol como inhibidores de la enzima pde10a. | |
TN2013000200A1 (en) | Imidazole derivatives as pde 10a enzyme inhibitors | |
TN2014000288A1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
CY1116689T1 (el) | Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a | |
MX2019014982A (es) | Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos. |